Drug News

Pharmacovigilance & Drug Safety Software Market to Hit $312 Million by 2030

Researchers have unveiled a comprehensive report that delves deep into the Pharmacovigilance and Drug Safety Software Market. This extensive analysis offers insights into various market segments and sub-segments on both a global and regional scale. It also delves into the impact of key drivers, restraints, and macro indicators on the global and regional pharmacovigilance and drug safety software market over both short and long-term periods.

Pharmacovigilance, a critical aspect of drug safety, encompasses a range of activities, including data collection, detection, assessment, monitoring, and prevention of adverse effects associated with pharmaceutical products. It plays a pivotal role in the life science industry, where stringent regulatory compliance is essential at every stage of the drug development, manufacturing, and commercialization process. Effective pharmacovigilance software solutions are crucial to ensure the safety and efficacy of pharmaceutical products throughout their lifecycle.

The scope of the pharmacovigilance and drug safety software market is extensive and continually expanding due to increasing regulatory demands, technological advancements, globalization of drug development, and a growing focus on patient safety. Key stakeholders in this market include pharmaceutical companies, healthcare providers, Contract Research Organizations (CROs), and other entities that rely on advanced software solutions to monitor, analyze, and ensure the safety of pharmaceutical products from development to market.

Here are the key findings from the report:

1. Impressive Market Growth: In 2022, the global pharmacovigilance and drug safety software market was valued at USD 188.14 million. The report predicts that it will surge to USD 311.98 million by 2030, with a substantial Compound Annual Growth Rate (CAGR) of 5.55% during the forecast period from 2023 to 2030.

2. Regulatory Drivers: Stringent regulations from esteemed government bodies such as the European Medicines Evaluation Agency (EMEA) and the U.S. Food and Drug Administration (FDA), with a primary focus on drug safety, are driving market growth. The pressure from these regulatory agencies to develop innovative and safe drugs is propelling the pharmacovigilance and drug safety software market on a global scale. Furthermore, the increasing incidence rate of Adverse Drug Reactions (ADRs) is expected to further boost market growth.

3. Challenges and Opportunities: While the adoption of pharmacovigilance software is on the rise, a shortage of skilled professionals in the field presents challenges to market growth. Nevertheless, ongoing research and development efforts aimed at creating more effective software solutions and increasing awareness of the benefits of pharmacovigilance and drug safety software are likely to create numerous growth opportunities in the coming years.

4. Regional Dominance: From a geographical perspective, North America is at the forefront of the pharmacovigilance and drug safety software market. This dominance is primarily due to the widespread adoption of pharmacovigilance and drug safety software, a well-developed healthcare infrastructure, and a high demand for new and safe drugs in the region. The Asia-Pacific region is experiencing the fastest growth in this market, driven by increased government investments in the pharmaceutical sector, rising demand for pharmacovigilance and drug safety software in hospitals and clinics, and other factors.

5. Segmented Analysis: The report offers a comprehensive breakdown of the pharmacovigilance and drug safety software market by software type, mode of delivery, and end-user. Sub-markets include drug adverse event reporting software, issue tracking software, fully integrated software, and drug safety audits software, along with modes of delivery such as on-premises and cloud-based. End-users encompass pharma & biotech companies, CROs, pharmacovigilance service providers, and business process outsourcing (BPO) firms.

6. Key Players: The report includes profiles of prominent companies in the market, such as IQVIA Inc, Oracle Corporation, Honeywell International Inc., AB Cube S.A.S., ArisGlobal, EXTEDO, Ennov, United BioSource LLC, Sarjen, and others.

The future of the pharmacovigilance and drug safety software market appears to be highly promising, with significant growth potential. Stringent regulations, a focus on patient safety, and the increasing incidence of adverse drug reactions are driving the adoption of advanced software solutions in the pharmaceutical industry. As the industry continues to evolve, the demand for effective pharmacovigilance and drug safety software is expected to rise, making it a critical area of interest for stakeholders across the healthcare and pharmaceutical sectors.


Dr. Oche Otorkpa PG Cert, MPH, PhD

Dr. Oche is a seasoned Public Health specialist who holds a post graduate certificate in Pharmacology and Therapeutics, an MPH, and a PhD both from Texila American University. He is a member of the International Society of Substance Use Professionals and a Fellow of the Royal Society for Public Health in the UK. He authored two books: "The Unseen Terrorist," published by AuthorHouse UK, and "The Night Before I Killed Addiction."
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker